WO2001008667A2 - 2-aminotetralin derivatives for the therapy of glaucoma - Google Patents
2-aminotetralin derivatives for the therapy of glaucoma Download PDFInfo
- Publication number
- WO2001008667A2 WO2001008667A2 PCT/EP2000/007184 EP0007184W WO0108667A2 WO 2001008667 A2 WO2001008667 A2 WO 2001008667A2 EP 0007184 W EP0007184 W EP 0007184W WO 0108667 A2 WO0108667 A2 WO 0108667A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chf
- iop
- glaucoma
- eye
- therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Definitions
- the present invention relates to the use of racemic or optically active compounds represented by formula I and the salts thereof
- R is H or CH3 , for the preparation of pharmaceutical compositions for the therapy of ophtalmic disorders.
- the invention relates to the use of ( ⁇ ) - (R, S) -5, 6-diisobutyroyloxy-2-methylamino-tetralin or its (-)-(S)- enantiomer in the preparation of ophthalmic formulations for the treatment of glaucoma.
- Glaucoma is an ophthalmic disorder characterized by increased intraocular pressure which causes excavation and degeneration of the optic disc. Notwithstanding the therapeutical progresses attained, glaucoma, whose etiology has not yet been completely clarified, is one of the main causes of irreversible blindness.
- glaucoma Three types of glaucoma are known: primary, secondary and congenital glaucoma.
- Primary glaucoma is, in turn, classified in acute congestive or angle-closure glaucoma and simple chronic or open-angle glaucoma.
- the high intraocular pressure (IOP) is due to insufficient outflow of the aqueous humour from the eye anterior chamber.
- the symptomatic therapy usually aims at decreasing the intraocular pressure, which can be attained via three mechanisms: i) increasing of the outflow of aqueous humor by use of direct parasympathomimetic or cholinesterase inhibitors; ii) dehydration of the eye bulbs by use of osmotic agents such as urea or mannitol; iii) reduction in the aqueous humor production by the ciliated epithelium: a number of medicaments, such as carbonic anhydrase inhibitors and ⁇ -blockers, act according to this mechanism.
- the medicaments of the various classes cited above can be administered either alone or in combinations thereof.
- Sympathomimetics have been widely used in the past, mainly in the treatment of open-angle glaucoma. These drugs act either through direct stimulation of adrenergic receptors or through release of catecholamines from the synaptic vesicles of the adrenergic nerve terminals. They differ both in their selectivity towards specific receptors and in the intensity of the adrenergic responses they give rise to. Depending on the type of receptors preferably involved, they can act either by promoting the outflow of aqueous humor or by decreasing its production.
- the search for drugs for the treatment of glaucoma is also directed to dopamine analogues for their capability of stimulating ⁇ -adrenoceptors in addition to the dopaminergic ones.
- dopamine analogues for their capability of stimulating ⁇ -adrenoceptors in addition to the dopaminergic ones.
- the decrease in intraocular pressure can take place through a plurality of mechanisms of action.
- some DA 2 -agonists were found particularly active; since they induce inhibition of catecholamines release in the eye, they can be functionally considered as indirectly acting ⁇ - blockers .
- dopaminergic medicaments a number of aminotetralin derivatives have been the object of several studies and Patent applications.
- CHF 1035 can be effectively used in the treatment of glaucoma through the topical administration .
- the 5, 6-diisobutyroyloxy-2-methylamino-tetralin derivative compared with the compound with the free catechol group at the 5,6 position or with other similar compounds (M-7) , has better characteristics in terms of chemical stability and ocular bioavailability, as proved by the higher partition coefficient n-octanol/buffer pH 7.4
- CHF 1035 can be advantageously used for the preparation of compositions for the ophthalmic use in the therapy of glaucoma. Even more preferred is the use of the corresponding (-)-(S) enantiomer which is about twice as much selective towards the ⁇ 2 and DA 2 receptors than the racemate .
- the present invention also includes the analogous derivative without the methyl group on the amino group.
- the compounds of the invention can be used in the form of salts with inorganic acids, such as hydrochloride and hydrobromide , or with organic acids such as acetate, tartrate and citrate.
- the amount of active ingredient to be used will vary with the age of the patient and the severity of the glaucoma .
- the concentration of the active ingredient will range from 0.001 to 5%, preferably between 0.01 and 1 . 0 % .
- the compounds can be formulated as aqueous solution or in the form of ointments, creams or gels, by using the conventional additives and excipients.
- Preferred carriers for the compounds of the invention are those consisting of a sterile isotonic aqueous solution, for the administration in the form of ophthalmic drops, containing viscosity-increasing agents such as hydroxypropylmethylcelluose, stabilizing agents such as EDTA or sodium bisulfite, preservatives such as benzalkonium chloride or chlorobutanol .
- the pH of the opthalmic composition will be adjusted between 3.0 to 7.5 by using conventional buffering agents such as borates, carbonates or phosphates. Preferably it will be adjusted between 4.0 and 5.0 avoiding buffers in order to manipulate the physiological environment of precorneal area as little as possible .
- the apparent partition coefficients (log P app ) of CHF 1035 were determined from the distribution of the compound between 1-octanol and phosphate buffer solution (50 mM; pH 1-4, 5.5, 6.5 and 7.4).
- the phosphate buffer solution and 1-octanol were saturated with each other, prior to partition study, by shaking vigorously for 24 h.
- a known concentration of CHF 1035 in the phosphate buffer solution was shaken 60 minutes with suitable volume of saturated 1- octanol . After shaking, the phases were separated by centrifugation, and the concentrations of CHF 1035 in the buffer phase were determined by HP C before and after partitioning.
- the results expressed as a mean ⁇ SD (standard deviation) are reported in Table 1.
- the higher apparent partition coefficient would be more favorable for ophthalmic absorption.
- an acid aqueous solution should be used as a vehicle for eyedrop administration due to the better chemical stability of CHF 1035 in such pH range.
- the theoretical log P app of the corresponding not esterified derivative turned out to be -0.9 at pH 7.4.
- Example 2 Intraocular pressure (IOP) studies after single dose in normotensive rabbits.
- pH 4.5 made isotonic with sodium chloride
- Buffer solution was not used in order to manipulate the physiological environment of precorneal area as little as possible. pH 4.5 was selected to confer a good stability to CHF 1035.
- the experimental animals used were normotensive Dutch
- CHF 1035 decreases significantly the IOP in the treated eye after topical administration into normotensive rabbits. However, no significant IOP decrease is observed in the untreated eye, which is considered to be a benefit.
- the minor IOP effects in untreated eye may mean minor systemic absorption and decreased risk for serious systemic side- effects .
- CHF 1035 shows a late onset of action which may be caused by its prodrug-nature .
- the maximum decrease in IOP occurs between 5 and 6 h with doses between 0.2 % and 1.0 %. In cases of smaller doses (i.e., doses 0.01 % and 0.05 %) , the maximum decrease in IOP tends to be earlier.
- the prodrug-nature may also prolong the duration of action of CHF 1035.
- CHF 1035 did not cause significant eye irritation in rabbits: no eyelid closure was observed after topical administration (25 ⁇ l) of 0.5%, 0,2%, 0.05% and 0.01% CHF 1035 solution. CHF 1035 also turned out to be more effective in decreasing IOP than brimonidine, and has longer duration of action than brimonidine.
- the IOP change was between -1.1 and 1.4 mmHg, and between 0.3 and 1.5 mmHg in the treated and in the untreated eye, respectively.
- IOP Intraocular pressure
- IOP Intraocular pressure
- CHF 1035 The effectiveness of CHF 1035 after repeated administration was tested in a study versus placebo, in 20 New-Zealand albino rabbits.
- each animal was intraocularly injected with 0.5 mg/day of ⁇ -chymotrypsin for five days. Starting from the first day of treatment, two drops of physiological saline containing 5% of the drug were instilled in each eye every 6 hours. The control animals only received physiological saline.
- the IOP measurement was performed as described in example 1, before the injection and subsequently every day until the 10 th day.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001513397A JP2003505499A (en) | 1999-07-30 | 2000-07-26 | 2-aminotetralin derivatives for the treatment of glaucoma |
AU68293/00A AU778148B2 (en) | 1999-07-30 | 2000-07-26 | 2-aminotetralin derivatives for the therapy of glaucoma |
AT00956296T ATE250413T1 (en) | 1999-07-30 | 2000-07-26 | 2-AMINOTETRALINE FOR THE TREATMENT OF GLAUCOMA |
EP00956296A EP1200079B1 (en) | 1999-07-30 | 2000-07-26 | 2-aminotetralin derivatives for the therapy of glaucoma |
US10/030,114 US6953813B1 (en) | 1999-07-30 | 2000-07-26 | 2-Aminotetralin derivatives for the therapy of glaucoma |
CA002379778A CA2379778A1 (en) | 1999-07-30 | 2000-07-26 | 2-aminotetralin derivatives for the therapy of glaucoma |
DE60005525T DE60005525T2 (en) | 1999-07-30 | 2000-07-26 | 2-AMINOTETRALINE FOR TREATING GLAUCOMA |
NO20020475A NO20020475L (en) | 1999-07-30 | 2002-01-29 | 2-aminotetraline derivatives for glaucoma therapy |
HK03100759.8A HK1048594A1 (en) | 1999-07-30 | 2003-01-30 | 2-aminotetralin derivatives for the therapy of glaucoma |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT1999MI001713A IT1313583B1 (en) | 1999-07-30 | 1999-07-30 | 2-AMINOTETRALINIC DERIVATIVES FOR GLAUCOMA THERAPY. |
ITMI99A001713 | 1999-07-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001008667A2 true WO2001008667A2 (en) | 2001-02-08 |
WO2001008667A3 WO2001008667A3 (en) | 2001-06-07 |
Family
ID=11383465
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/007184 WO2001008667A2 (en) | 1999-07-30 | 2000-07-26 | 2-aminotetralin derivatives for the therapy of glaucoma |
Country Status (17)
Country | Link |
---|---|
US (1) | US6953813B1 (en) |
EP (1) | EP1200079B1 (en) |
JP (1) | JP2003505499A (en) |
CN (1) | CN1170532C (en) |
AT (1) | ATE250413T1 (en) |
AU (1) | AU778148B2 (en) |
CA (1) | CA2379778A1 (en) |
CZ (1) | CZ2002358A3 (en) |
DE (1) | DE60005525T2 (en) |
ES (1) | ES2207544T3 (en) |
HK (1) | HK1048594A1 (en) |
HU (1) | HUP0202098A3 (en) |
IT (1) | IT1313583B1 (en) |
NO (1) | NO20020475L (en) |
PL (1) | PL364794A1 (en) |
WO (1) | WO2001008667A2 (en) |
ZA (1) | ZA200200787B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001085668A1 (en) * | 2000-05-12 | 2001-11-15 | Chiesi Farmaceutici S.P.A. | Optically active 2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them |
WO2009089284A2 (en) * | 2008-01-09 | 2009-07-16 | Allergan, Inc. | Substituted 2-aminotetralin derivatives as selective alpha 2b agonist |
JP2010132681A (en) * | 2001-05-03 | 2010-06-17 | Allergan Inc | Composition having enhanced pharmacokinetic characteristics |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2218442A1 (en) | 2005-11-09 | 2010-08-18 | CombinatoRx, Inc. | Methods, compositions, and kits for the treatment of ophthalmic disorders |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0009702A1 (en) * | 1978-09-20 | 1980-04-16 | Schering Corporation | A phenylalkylaminoethylsalicylamide, its preparation and pharmaceutical compositions containing it |
GB2123410A (en) * | 1982-06-10 | 1984-02-01 | Chiesi Farma Spa | New derivatives of 1,2,3,4-tetrahydronaphthalene, process for their preparation and associated pharmaceutical compositions |
US5236907A (en) * | 1988-10-01 | 1993-08-17 | R-Tech Ueno Ltd. | Ocular hypotensive agents |
WO1996029065A2 (en) * | 1995-03-17 | 1996-09-26 | Chiesi Farmaceutici S.P.A. | Aminotetralin derivative for the therapy of cardiovascular diseases |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5314916A (en) * | 1993-04-19 | 1994-05-24 | Alcon Laboratories, Inc. | B2 adrenegic agonists and use thereof in the treatment of glaucoma |
-
1999
- 1999-07-30 IT IT1999MI001713A patent/IT1313583B1/en active
-
2000
- 2000-07-26 CZ CZ2002358A patent/CZ2002358A3/en unknown
- 2000-07-26 AT AT00956296T patent/ATE250413T1/en not_active IP Right Cessation
- 2000-07-26 EP EP00956296A patent/EP1200079B1/en not_active Expired - Lifetime
- 2000-07-26 AU AU68293/00A patent/AU778148B2/en not_active Ceased
- 2000-07-26 WO PCT/EP2000/007184 patent/WO2001008667A2/en not_active Application Discontinuation
- 2000-07-26 CN CNB008108676A patent/CN1170532C/en not_active Expired - Fee Related
- 2000-07-26 DE DE60005525T patent/DE60005525T2/en not_active Expired - Fee Related
- 2000-07-26 JP JP2001513397A patent/JP2003505499A/en active Pending
- 2000-07-26 HU HU0202098A patent/HUP0202098A3/en unknown
- 2000-07-26 PL PL00364794A patent/PL364794A1/en not_active Application Discontinuation
- 2000-07-26 US US10/030,114 patent/US6953813B1/en not_active Expired - Fee Related
- 2000-07-26 CA CA002379778A patent/CA2379778A1/en not_active Abandoned
- 2000-07-26 ES ES00956296T patent/ES2207544T3/en not_active Expired - Lifetime
-
2002
- 2002-01-29 ZA ZA200200787A patent/ZA200200787B/en unknown
- 2002-01-29 NO NO20020475A patent/NO20020475L/en not_active Application Discontinuation
-
2003
- 2003-01-30 HK HK03100759.8A patent/HK1048594A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0009702A1 (en) * | 1978-09-20 | 1980-04-16 | Schering Corporation | A phenylalkylaminoethylsalicylamide, its preparation and pharmaceutical compositions containing it |
GB2123410A (en) * | 1982-06-10 | 1984-02-01 | Chiesi Farma Spa | New derivatives of 1,2,3,4-tetrahydronaphthalene, process for their preparation and associated pharmaceutical compositions |
US5236907A (en) * | 1988-10-01 | 1993-08-17 | R-Tech Ueno Ltd. | Ocular hypotensive agents |
WO1996029065A2 (en) * | 1995-03-17 | 1996-09-26 | Chiesi Farmaceutici S.P.A. | Aminotetralin derivative for the therapy of cardiovascular diseases |
Non-Patent Citations (1)
Title |
---|
MORISCO CARMINE ET AL: "Hemodynamic effects of graded oral doses of a new dopaminergic analogue CHF 1035 in patients with congestive heart failure." JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, no. SPEC. ISSUE, 1995, page 128A XP000989553 44th Annual Scientific Session of the American College of Cardiology;New Orleans, Louisiana, USA; March 19-22, 1995 ISSN: 0735-1097 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001085668A1 (en) * | 2000-05-12 | 2001-11-15 | Chiesi Farmaceutici S.P.A. | Optically active 2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them |
JP2010132681A (en) * | 2001-05-03 | 2010-06-17 | Allergan Inc | Composition having enhanced pharmacokinetic characteristics |
WO2009089284A2 (en) * | 2008-01-09 | 2009-07-16 | Allergan, Inc. | Substituted 2-aminotetralin derivatives as selective alpha 2b agonist |
WO2009089284A3 (en) * | 2008-01-09 | 2009-10-15 | Allergan, Inc. | Substituted 2-aminotetralin derivatives as selective alpha 2b agonist |
US7829587B2 (en) | 2008-01-09 | 2010-11-09 | Allergan, Inc. | Substituted 2-aminotetralin derivatives as selective alpha 2B agonist |
Also Published As
Publication number | Publication date |
---|---|
ZA200200787B (en) | 2003-03-26 |
HK1048594A1 (en) | 2003-04-11 |
EP1200079B1 (en) | 2003-09-24 |
AU6829300A (en) | 2001-02-19 |
AU778148B2 (en) | 2004-11-18 |
HUP0202098A2 (en) | 2002-10-28 |
CZ2002358A3 (en) | 2002-04-17 |
ES2207544T3 (en) | 2004-06-01 |
NO20020475L (en) | 2002-03-13 |
EP1200079A2 (en) | 2002-05-02 |
CA2379778A1 (en) | 2001-02-08 |
HUP0202098A3 (en) | 2003-08-28 |
PL364794A1 (en) | 2004-12-13 |
ITMI991713A0 (en) | 1999-07-30 |
DE60005525T2 (en) | 2004-04-22 |
JP2003505499A (en) | 2003-02-12 |
CN1170532C (en) | 2004-10-13 |
CN1364081A (en) | 2002-08-14 |
US6953813B1 (en) | 2005-10-11 |
DE60005525D1 (en) | 2003-10-30 |
ATE250413T1 (en) | 2003-10-15 |
WO2001008667A3 (en) | 2001-06-07 |
NO20020475D0 (en) | 2002-01-29 |
IT1313583B1 (en) | 2002-09-09 |
ITMI991713A1 (en) | 2001-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109528721B (en) | Combination therapy | |
JP6060168B2 (en) | An anterior eye disease therapeutic agent comprising rebamipide and a drug having a lacrimal fluid retention action | |
EP0771563B1 (en) | Use of 5-HT1A receptor ligands for the treatment of glaucoma | |
US5438060A (en) | Method of reducing elevated intraocular pressure | |
US4565821A (en) | Method and ophthalmic composition for treating ocular hypertension and glaucoma with butyrophenones | |
EP0403360B1 (en) | Use of phenylethanolamines for the preparation of a medicament for treating ophthalmologic disorders | |
AU778148B2 (en) | 2-aminotetralin derivatives for the therapy of glaucoma | |
JP7346305B2 (en) | Pharmaceutical preparations containing pyridylaminoacetic acid compounds | |
EP2119440A1 (en) | Amidino derivatives for use in the prevention or treatment of retinitis pigmentosa and Leber's disease | |
US20110160267A1 (en) | Method of treating diabetic retinopathy | |
TW304879B (en) | ||
US4764530A (en) | Pharmaceutical compositions and their use as mydriatics | |
JPWO2006098292A1 (en) | Eye disease treatment | |
EP0728480A1 (en) | Use of ifenprodil for treatment of elevated intraocular pressure | |
TWI842692B (en) | Pharmaceutical preparations containing pyridinylaminoacetic acid compounds | |
JP2741285B2 (en) | Glaucoma treatment | |
US5428030A (en) | Method of reducing elevated intraocular pressure | |
JPWO2002051431A1 (en) | Agent for treating and / or preventing diseases based on retinal ischemia | |
CN118217292A (en) | Triple compound pharmaceutical composition for treating glaucoma | |
JPH02255618A (en) | Remedy for glaucoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 516401 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000956296 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 008108676 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2002-358 Country of ref document: CZ Ref document number: 2002/00787 Country of ref document: ZA Ref document number: 68293/00 Country of ref document: AU Ref document number: 2379778 Country of ref document: CA Ref document number: 200200787 Country of ref document: ZA |
|
WWP | Wipo information: published in national office |
Ref document number: PV2002-358 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10030114 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2000956296 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000956296 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 516401 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 516401 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 68293/00 Country of ref document: AU |
|
WWR | Wipo information: refused in national office |
Ref document number: PV2002-358 Country of ref document: CZ |